According to the Zhitong Finance App, China Antibody-B (03681) announced its 2026 interim results. Other revenue and revenue were 234.62 million yuan, up 139.36% year on year; research and development costs were 503.37 million yuan, up 53.75% year on year; net loss was about 127 million yuan.
During the reporting period and up to the date of this announcement, the company made a number of significant developments in its product pipeline. Core products have reached phased milestones in clinical development, indication expansion and regulatory reporting, and several projects have also achieved important regulatory milestones. The core asset SM17 has shown excellent anti-itching effects, skin damage recovery efficacy and safety in the treatment of atopic dermatitis (AD), and has potential for use in asthma, idiopathic pulmonary fibrosis (IPF), and inflammatory bowel disease (IBD). The anti-CD22 antibody suciraslimab (Suciraslimab) has shown clinical efficacy in rheumatoid arthritis (RA) and is being evaluated for systemic lupus erythematosus (SLE). We are also developing an innovative anti-CGC (common gamma chain) monoclonal antibody, which has shown encouraging preclinical activity in alopecia areata and vitiligo models through a mechanism of action different from JAK inhibitors. Through continuous innovation and strict implementation, the company is committed to developing differentiated therapies for significant unmet medical needs.
The efficient and asset-light model is the Group's long-term strategy. During the reporting period and up to the date of this announcement, the Group successfully concluded an agreement to dispose of its Suzhou properties and facilities at a cost of RMB 280 million. The net proceeds from the sale are expected to strengthen the Group's working capital position and improve cash flow, thereby providing additional financial flexibility to support the Group's R&D activities, clinical projects, pipeline advancement and other operating needs. The Group believes that this sale will enable the Group to focus its financial and management resources on its core business.